Drug Trial Radar · NCT07679113
IPG1094 Phase I Study for China Healthy Participants
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Jan 30, 2027
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Nanjing Immunophage Biotech Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Xuhui Central Hospital, Shanghai
- First posted
- Jul 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 open-label study enrolls 24 healthy Chinese adults to investigate the pharmacokinetics, safety and tolerability of oral IPG1094 tablets. The trial includes two parts. Part A (12 participants) uses a crossover design to explore the impact of food on a single 200 mg dose of IPG1094; participants will receive the drug under fasting and post-meal conditions on separate days, with intensive blood sampling for PK analysis. Part B (12 participants) evaluates multiple-dose PK, where participants take 200 mg IPG1094 twice daily for 10 days to observe drug exposure and accumulation. All participants will undergo comprehensive safety checks such as lab tests, ECG and adverse event monitoring during screening, treatment and post-dosing follow-up. No placebo or blinding is applied in this study.
Conditions
- Healthy Volunteers
Interventions
IPG1094 TabletsDrug
Part A:Oral administration with 240 mL water; fasted: ≥10h overnight fast, no water 1h before/after dosing; fed: take drug within 30 mins of finishing standardized high-fat breakfast. Single dose 200 mg per cycle, two cycles separated by 5-day washout. Part B:Oral 200 mg twice daily, morning \& evening, continuous 10 days; each dose taken with 240 mL water, restricted water intake 1h pre/post dose; steady-state PK sampling for accumulation assessment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A:Time to maximum concentration (Tmax)Time frame: Full PK sampling profiles on Day 1 and Day 6
- Part A:Plasma maximum concentration (Cmax)Time frame: Full PK sampling profiles on Day 1 and Day 6
- Part A:Terminal elimination half-life (t1/2)Time frame: Serial blood samples collected up to 96 hours post-dose on Day 1 and Day 6
- Part B:Steady-state maximum plasma concentration (Css,max)Time frame: Full PK sampling profiles on Day 10
- Part B:Time to steady-state maximum concentration (Tss,max)Time frame: Full PK sampling profiles on Day 10
- Part B:Steady-state terminal elimination half-life (t1/2)Time frame: Serial blood samples collected up to 72 hours post-dose on Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, Xuhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.